Verseon and NeuTherX Partner to Boost Drug Development Efforts
Wednesday, July 31, 2024
Verseon and NeuTherX are thrilled to announce a new partnership designed to enhance drug development through NeuTherX's advanced organoid cultivation technology.
Verseon is committed to refining the drug development process, focusing on creating treatments for major human diseases. Traditionally, understanding drug behavior in humans requires extensive and expensive clinical trials. However, gaining early insights through lab-based models can greatly streamline these trials.
Organoids—lab-grown clusters of cells that mimic the functions of human organs—are central to Verseon's strategy. By testing drugs on organoids, the company can gather crucial preliminary data on their potential effects in real patients, potentially minimizing the need for extensive human trials.
While Verseon continues to advance its own technologies, it also seeks collaborations that can enhance its efforts. NeuTherX, with its expertise in scalable organoid development, has previously concentrated on psychiatric drug research but is now expanding its technology to other areas.
This collaboration will integrate NeuTherX's scalable organoid technology into Verseon's drug development framework.
"At Verseon, we are dedicated to generating innovative drug candidates and understanding their potential impact on humans," said Adityo Prakash, CEO of Verseon. "NeuTherX's technology will greatly enhance our ability to predict drug behavior and improve trial design."
Richard Hoopes, CEO of NeuTherX, added, "We believe organoid-based testing represents the future of drug candidate evaluation. Partnering with Verseon allows us to apply our technology to a wide range of diseases and advance the field together."
Source: prnewswire.com
